Invenio Imaging Strengthens Board with New Directors to Enhance Leadership

Invenio Imaging Strengthens Board with New Appointments

Invenio Imaging, renowned for its advancements in fresh tissue imaging and artificial intelligence, has recently made significant changes to its leadership team. The company has appointed Adrian Whitford as an Independent Board Director, alongside welcoming Biao He from Oak BioCapital and John Seamans from Michigan Biomedical Venture Fund to its Board of Directors. This strategic alignment is set to bolster the company's commercialization efforts as it strives to enhance the efficiency of its clinical workflows.

Background on New Appointees

Adrian Whitford comes to Invenio Imaging with an impressive track record in global commercialization and marketing within the oncology and digital health sectors. Prior to this new role, he served as the Worldwide President for Monarch Robotics and the Lung Cancer Initiative at Johnson & Johnson MedTech. His responsibilities there involved leading the commercialization process for robotic bronchoscopy, an innovative approach that has been implemented at scale. Currently, Whitford holds the position of President at Biobot Surgical, focusing on robotic-assisted diagnosis and treatment of prostate cancer.

Whitford has a strong foundation in enhancing patient outcomes through digital health initiatives, which he brings to Invenio Imaging at a critical juncture as the company aims to expand its market presence. He expressed his enthusiasm for joining the board, stating, "I'm excited to join Invenio's board and support the team as they bring timely, actionable information into procedure-driven cancer care."

Why This Matters

The addition of new board members comes at a pivotal moment as Invenio Imaging seeks to broaden access to its cutting-edge platform, which integrates rapid fresh tissue imaging with AI-driven analysis. Jay Trautman, President and CEO of Invenio Imaging, emphasized the importance of Whitford's extensive experience in lung cancer commercialization, prostate cancer markets, and digital health in aiding the company’s mission: "Adrian has a proven track record of translating clinically meaningful innovation into a clear value narrative that accelerates adoption."

The newly expanded board also reflects a commitment to continue fostering strategic partnerships that can enhance innovation in the medical field. Biao He’s arrival from Oak BioCapital signals the firm’s first investment in Invenio, further supporting the company’s growth trajectory. Meanwhile, John Seamans brings invaluable insights from the Michigan biomedical sector, reinforcing Invenio's medtech leadership with a wealth of industry experience.

Looking Forward

Invenio Imaging previously announced that it received FDA Breakthrough Device Designation for its NIO® Lung Cancer Reveal module, an AI image-analysis tool designed to assist healthcare providers in evaluating images from lung biopsy specimens. While the module is still under investigation and not yet approved for clinical use in the United States, it represents a significant step forward in cancer care. The company plans to leverage its board’s expertise to navigate the complexities of commercialization and to bring this innovative tool to market effectively.

With the guidance of its newly appointed board members, Invenio Imaging is poised to enhance its focus on broadening access to its innovative platform that supports efficient clinical workflows and ultimately improves patient care. The team at Invenio is excited about the possibilities that lie ahead as they continue to redefine the landscape of diagnostic imaging and AI in medicine.

About Invenio Imaging

Invenio Imaging Inc. is a private medical device company located in Santa Clara, California, dedicated to enhancing the care of cancer patients through advanced intraoperative fresh tissue imaging and artificial intelligence. The NIO® Laser Imaging System, which has been registered with the FDA and received the CE mark, has been successfully utilized in over 12,500 procedures across diverse medical fields including neurosurgery and urology.

The NIO® Glioma Reveal, the company’s first AI product, has also been granted CE marking and is available for clinical use in Europe. Invenio remains steadfast in its mission to integrate innovation and technology towards transforming cancer diagnostics and treatment.